Premium
Osteoclastogenesis and osteoclastic resorption of tricalcium phosphate: Effect of strontium and magnesium doping
Author(s) -
Roy Mangal,
Bose Susmita
Publication year - 2012
Publication title -
journal of biomedical materials research part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 150
eISSN - 1552-4965
pISSN - 1549-3296
DOI - 10.1002/jbm.a.34181
Subject(s) - osteoclast , rankl , bone resorption , resorption , materials science , microbiology and biotechnology , cellular differentiation , vitronectin , medicine , receptor , activator (genetics) , chemistry , biology , biochemistry , integrin , gene
Abstract Bone substitute materials are required to support the remodeling process, which consists of osteoclastic resorption and osteoblastic synthesis. Osteoclasts, the bone‐resorbing cells, generate from differentiation of hemopoietic mononuclear cells. In the present study, we have evaluated the effects of 1.0 wt % strontium (Sr) and 1.0 wt % magnesium (Mg) doping in beta‐tricalcium phosphate (β‐TCP) on the differentiation of mononuclear cells into osteoclast‐like cells and its resorptive activity. In vitro osteoclast‐like cell formation, adhesion, and resorption were studied using osteoclast precursor RAW 264.7 cell, supplemented with receptor activator of nuclear factor κβ ligand (RANKL). Osteoclast‐like cell formation was noticed on pure and Sr‐doped β‐TCP samples at day 8, which was absent on Mg‐doped β‐TCP samples indicating decrease in initial osteoclast differentiation due to Mg doping. After 21 days of culture, osteoclast‐like cell formation was evident on all samples with osteoclastic markers such as actin ring, multiple nuclei, and presence of vitronectin receptor α v β 3 integrin. After osteoclast differentiation, all substrates showed osteoclast‐like cell‐mediated degradation, however, significantly restricted for Mg‐doped β‐TCP samples. Our present results indicated that substrate chemistry controlled osteoclast differentiation and resorptive activity, which can be used in designing TCP‐based resorbable bone substitutes with controlled degradation properties. © 2012 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 100A: 2450–2461, 2012.